Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …

This article proposes codes for the primary tumor categories of adenocarcinoma in situ (AIS)
and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in …

Background Previous studies have demonstrated the efficacy and safety of bevacizumab in
the treatment of non-small-cell lung cancer (NSCLC). Methods Summary data from …

… analysed by our statistical partners at Cancer Research And Biostatistics and, in close
collaboration with the members of the committee proposals have been developed for the T, N, and …

Background Previous, uncontrolled studies have suggested that first-line treatment with
gefitinib would be efficacious in selected patients with non–small-cell lung cancer. Methods In …

Background Irinotecan hydrochloride, a topoisomerase I inhibitor, is effective against small-cell
lung cancer. In a phase 2 study of irinotecan plus cisplatin in patients with extensive small…

… patients with low EGFR gene copy number (n … CI, 0.64 to 1.48; P .893; n 99). ORRs were
similar between the gefitinib … , 53.6% (n 140) had tumors with exon 19 deletions, and 42.5% (n …

Background: To compare the efficacy and toxicity of three platinum-based combination
regimens against cisplatin plus irinotecan (IP) in patients with untreated advanced non-small-cell …

PURPOSE: To evaluate the optimal timing for thoracic radiotherapy (TRT) in limited-stage
small-cell lung cancer (LS-SCLC), the Lung Cancer Study Group of the Japan Clinical …

… In North America and in European countries, docetaxel, 3,4 pemetrexed, 2 and erlotinib 5 …
Interstitial lung disease events occurred in 5.7% (n = 14) and 2.9% (n = 7) of patients who …